Fig. 1

CU06-1004 reduced mortality and attenuated pulmonary damages in LPS-induced acute lung injury model. (A) Experimental scheme of study. For assessment of survival, mice were treated with CU06-1004 or dexamethasone every 12 h for 4 days. Sample collections for other tests were performed after one day. The first drug treatment was 4 h after LPS challenge, and mice were sacrificed 4 h after the final treatment. (B) The survival rate in each group was determined every 12 h for 4 days after a lethal-dose LPS challenge: PBS group (black line), LPS group (red line), LPS + CU06-1004 group (blue line), and LPS + dexamethasone group (green line). Results expressed as percentage of live mice at each time point. N = 15 per group. ### p < 0.001 vs. PBS, ** p < 0.005 vs. LPS, log-rank tests. (C) Representative H&E-stained images of sections from mouse lungs. Lung injury indicated by infiltration of immune cells, interstitial hemorrhage (red arrows), congestion (black arrows), and thickened alveolar walls (two headed arrows, red). N = 6 per group. Magnification, 100X (upper panel) and 400X (lower panel). Scale bar: 30 μm. (D) Histological scores evaluated according to the grades as described in methods section. Results presented as mean ± SEM values; *** p < 0.001. (E) Lung wet/dry weight ratios determined one day after LPS challenge. N = 8 per group. Results presented as mean ± SD values; * p < 0.05. (F) Arterial oxygen concentration was measured by pulse oximeter. N = 5 per group, Results presented as mean ± SD values; ** p < 0.01, *** p < 0.001. (G) scanning electron microscopy images, low magnification (1,000X, upper panel) and high magnification (2,000X, lower panel). Normal pulmonary capillaries (yellow arrows) and alveolar wall thickening (two-headed arrow, red) were shown. Scale bar: 10 μm